
LLY
股票Eli Lilly and Co
- 总部
- US
- 行业
- 制药
- 发行时间
- 1985-01-13
- 流通股
- 942M
区间表现
4 天前关键指标
4 天前- 市值
- $1.06T
- 企业价值
- $1.10T
- 市盈率 (TTM)
- 41.85
- 预期市盈率
- 24.92
- 市盈率 (年)
- 51.25
- PEG
- 1.29
- 市净率
- 38.29
- 市销率 (TTM)
- 14.64
- 市销率 (年)
- 16.23
- EV / EBITDA
- 32.65×
- EV / 营收
- 15.17×
- 每股收益 (TTM)
- $28.15
- 每股收益 (年)
- $22.95
- 基本每股收益 (TTM)
- $28.15
- 每股净资产
- $28.09
- 毛利率
- 82.83%
- 营业利润率
- 43.63%
- 净利率
- 34.99%
- 净资产收益率 (ROE)
- 101.31%
- 总资产收益率 (ROA)
- 22.73%
- 投资回报率 (ROI)
- 37.71%
- 每股 EBITDA
- $37.37
- 每股营收 (TTM)
- $80.64
- 营收增长 (TTM YoY)
- +47.44%
- 营收增长 (季 YoY)
- +55.55%
- EPS 增长 (TTM YoY)
- +128.83%
- 股息率 (预期)
- 0.61%
- 股息率 (TTM)
- 0.53%
- 每股股息 (TTM)
- $5.91
- 派息率
- 22.10%
- 流动比率
- 1.58
- 速动比率
- 0.78
- 负债权益比
- 1.60
- 长期负债权益比
- 1.54
- Beta
- 0.53
- 波动率 (3M)
- 37.23%
分析师评级
4 天前财报
4 天前相关新闻
4 天前- Yahoo·5 天前companyCVS will add these weight-loss options to drug plans
CVS Health will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin coverage of the anti-obesity pill Foundayo.
- SeekingAlpha·5 天前companyEli Lilly and Company (LLY) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Eli Lilly and Company (LLY) Bernstein 42nd Annual Strategic Decisions Conference May 28, 2026 1:30 PM EDTCompany ParticipantsDaniel Skovronsky - Chief...
- Yahoo·5 天前companyLilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), Mounjaro (tirzepatide), Foundayo (orforglipron) and retatrutide, will present new data across its cardiometabolic portfolio at the American Diabetes Association's 86th Scientific Sessions taking place June 5-8 in New Orleans. Together, these findings position Lilly to lead the next era of cardiometabolic care, with a differentiated suite of approved and investigational medicines built to expand choice for the millions living
- Yahoo·5 天前companyAAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine
SEATTLE, May 28, 2026--The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Curevo Vaccine on Lilly’s acquisition of Curevo.
- Yahoo·5 天前companyLLY Stock Hits All-Time High — CVS Coverage Boost For Zepbound May Be Driving Gains
CVS Health’s decision to expand formulary coverage for key GLP-1 therapies marks a boost for Eli Lilly's obesity drug business.
- Yahoo·5 天前companyEli Lilly Stock Heads for Record Close. CVS Weight-Loss Drug Coverage Drives It Higher.
CVS Health’s Caremark will resume insurance coverage of Eli Lilly’s Zepbound and separately begin covering its Foundayo weight-loss pill.
- Yahoo·5 天前companyTop Midday Stories: US Reportedly Reaches Deal With Iran, Needs Trump's Approval; Caesars to be Acquired by Fertitta for $17.6 Billion
The S&P 500 and Nasdaq Composite were up, while the Dow Jones Industrial Average was down slightly i
- Benzinga·5 天前companyWhy Is Eli Lilly Stock Surging On Thursday?
Eli Lilly (NYSE:LLY) shares jumped on Thursday morning after securing expanded PBM coverage for its blockbuster obesity treatments, Zepbound and Foundayo.


